Brief: Bioarctic Says Leqembi-Data Suggests Potential To Delay Disease Progression
Dec 4 (Reuters) - BioArctic AB BIOAb.ST: NEW LEQEMBI-DATA PRESENTED AT CTAD 2025 SUGGESTS POTENTIAL TO DELAY DISEASE PROGRESSION BY UP TO 8.3 YEARS WITH CONTINUED TREATMENT Source text: ID:nWkr3mnfZJ Further company coverage: BIOAb.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million